Modernizing Commercialization at JPM and Biotech Showcase 2027
Modernize Commercialization With EVERSANA at Biotech Showcase 2027
Meet our commercialization experts at Informa’s Biotech Showcase™ during J.P. Morgan Healthcare Conference week to discuss the decisions that can shape the future of your asset and your organization. From launch strategy and market access to integrated commercialization models, we’ll help you explore your options and determine the right path forward.
A Connected Approach Across the Commercial Lifecycle
Secure Access
Clear the barriers between your therapy and the patients who need it with smarter strategies that strengthen access, affordability, and reach.
SCHEDULE A MEETING
Accelerate Adoption
Drive Adherence
Keep patients moving forward with connected support that removes friction, strengthens engagement, and helps more people stay on therapy.
SCHEDULE A MEETINGJoin Our Biotech Showcase Fireside Chat
Modernizing Commercialization: Three Decisions That Maximize Enterprise Value
San Francisco, CA | Monday, January 11, 2027 | Imperial Ballroom | 10:30–10:50 a.m. Pacific
For emerging biopharma companies, commercialization is not simply the final step before launch. It is a series of enterprise-defining decisions that can determine an asset’s reach, a company’s capital efficiency, and its long-term value.
In this fireside chat, experienced biopharma and commercialization leaders will examine three critical decisions facing first-time launchers:
- Whether to out-license or retain control through a self-launch
- Whether to build internal commercial infrastructure or partner through an integrated, outsourced commercialization model
- How to prioritize and sequence global markets to maximize asset and enterprise value
The discussion will explore how first-time launchers can move beyond the traditional, fragmented commercialization playbook and configure a model built around their asset, patient population, capital strategy, and growth ambitions.
Featured Speakers
- Farah Ahmad, Executive Vice President, Business Development, Commercial, EVERSANA
- Phil Tennant, Chief Commercial Officer, Precigen
- Michael Overdorf, Executive Vice President & Chief Business Officer, Annexon Biosciences
- Jennifer Meeuwsen, Executive Vice President, COMPLETE, General Medicine, EVERSANA
In San Francisco January 11–14?
Let’s Modernize Commercialization, Together.
The Commercialization Playbook Is Broken. We're Building a New One.
Biopharma leaders need a new way to bring therapies to market.
Increasing pressure on established and emerging pharmaceutical companies, investment market volatility, regional and regulatory complexity, and the need to improve both brand value and patient impact have exposed the limitations of the traditional, fragmented commercialization playbook.
Explore commercialization models configured around your asset, patient population, lifecycle stage, and growth ambitions.
EVERSANA COMPLETE Commercialization®
An integrated commercialization model configured around your asset, patient population, and growth ambitions.
Mitigate risk. Move faster. Avoid building costly infrastructure.
EVERSANA REIGNITE™
Reduce costs, sustain revenue, and unlock greater value from established brands with an AI-enabled commercialization model.